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Summary.-The addition of misonidazole (MISO) or metronidazole (METRO) to
treatment with cyclophosphamide (CY) increased delay to regrowth of 2 experi-
mental tumours. The effect was observed for large and small tumours, was present
for doses of MISO that are ineffective for killing hypoxic cells, and required that it be
given with, or shortly before CY. Mice receiving combined treatment had more
weight loss and myelosuppression than those receiving CY alone, and the Therapeutic
Index was lower.
MISO caused a marked increase in growth delay when combined with BCNU to
treat the KHT sarcoma. This effect was observed for small and large tumours,
required simultaneous administration of drugs, and also led to increased host
toxicity. There was no therapeutic advantage from combined treatment.
Survival of aerobic or anoxic Chinese hamster ovary (CHO) cells was assessed
after exposure in vitro to serum from mice that had received CY or BCNU alone,
MISO alone, or combined treatment. Results of these experiments suggest that
(1) MISO delays the excretion or breakdown of active metabolites of CY, and (2) at a
dose that does not kill hypoxic cells, it may selectively "sensitize" hypoxic cells (but
not aerobic cells) to the action of BCNU. The presence of other undetermined inter-
actions of BCNU and MISO is inferred from the increased toxicity to (aerobic)
normal tissue.
Misonidazole or metronidazole should
receiving BCNU or cyclophosphamide.
CYCLOPHOSPHAMIDE (CY) was reported
to kill selectively the well-oxygenated cells
of a transplantable rat tumour, and to
spare the hypoxic, radioresistant cells
(Dixon et al., 1978). A similar effect was
reported for the action of BCNU against
B]6 melanoma in mice, but CY had no
selectivity for well-oxygenated cells ofthis
tumour (Hill & Stanley, 1975). The
mechanism ofthese effects is unknown, but
potential causes of drug resistance of
hypoxic and poorly nourished cells in solid
tumours include limited diffusion of the
drugs or their active metabolites from
blood vessels, and a lower rate of cell
proliferation for poorly nourished cells
than for those situated closer to blood
be used with caution in patients who are
vessels (Tannock, 1968, 1970; Hirst &
Denekamp, 1979).
If hypoxic cells in some solid tumours
are resistant to CY or BCNU, an improved
therapeutic index (i.e. ratio of tumour
damage to normal tissue damage) might
be achieved by combining them with
agents that have selective toxicity for
hypoxic cells. MISO and METRO are
drugs that are known to have selective
toxicity for hypoxic cells in tissue culture
and in spheroids (Mohindra & Rauth, 1976;
Sridhar et al., 1976; Stratford & Adams,
1977; Taylor & Rauth, 1978) and have
been shown to kill hypoxic (and perhaps
neighbouring aerobic cells) in some, but
not all mouse tumours (Foster et al., 1976;I. F. TANNOCK
Brown, 1977; Denekamp, 1978; Brown &
Yu, 1979).
The preceding paper (Tannock, 1980)
reported a study ofthe interaction in mice
of methotrexate, 5-fluorouracil or Adria-
mycin with MISO or METRO, using the
endpoints of growth delay of two ex-
perimental tumours, and of weight loss
and myelosuppression to assess host
toxicity. I now report similar studies of
the combination of CY with single or
multiple doses of MISO or METRO and
ofBCNU with single-dose MISO. I include
experiments designed to studythemechan-
isms underlying the large interactions that
have been observed.
MATERIALS AND METHODS
C3H male mice were used in all experi-
ments, and the experimental tumours were
theKHTfibrosarcoma andthe 16/Cmammary
adenocarcinoma (Lin & Bruce, 1972; Corbett
et al., 1978). Characteristics ofthese tumours,
techniques for implantation and assessment
oftumour growth, and methods for measuring
haemoglobin level (Hb) and white blood cell
counts (WBC) on peripheral blood, have been
described in the preceding paper (Tannock,
1980). Unless stated otherwise, mice received
drug treatment when their tumours were
0-3-0 5 g in size. All measurements were
made without knowledge of the treatment
history ofthe animals, and most experiments
were repeated to check reproducibility.
For treatment of the mice, Cyclophospha-
mide (Horner), Misonidazole (Roche), and
Metronidazole (Poulenc) were dissolved in
saline forinjection, while BCNU was dissolved
in 10% ethanol. Drugs were given by i.p.
injection in a fluid volume of 0.1 mg/g body
weight (CY or BCNU) or 0-02-0-05 ml/g
(MISO or METRO). Single injections of CY
or BCNU were used in all experiments.
MISO was injected usually as a single dose of
1 mg/g body weight, but multiple i.p. injec-
tions ofMISO or METRO were given in some
experiments in combination with CY. Nine
doses of 0-2 mg/g/injection (MISO) or 0 4
mg/g/injection (METRO) were injected at
4h intervals in an attempt to sustain serum
levels over 36 h (Tannock, 1980).
The mechanism of interaction of MISO
with CY or BCNU was investigated by expos-
ing Chinese hamster ovary (CHO) cells to
serum from mice that had been treated with
drugs. Blood was obtained from the inferior
vena cava of mice that had received CY or
BCNU alone, MISO alone, or a combination.
Heparin was injected shortly before death to
prevent clotting, and the interval between
drug treatment and death was 0 5 or 1 0 h.
Pooled blood from several mice was placed on
ice and centrifuged; the serum was filtered,
and 0 5 ml volumes of serum from mice that
had received different treatments were added
to vials containing 7*5 ml of a suspension of
CHO cells. The cells were in complete ox-
medium supplemented with antibiotics and
10% foetal calf serum (FCS) at a concentra-
tion of 5 x 105/ml and were agitated gently
with a magnetic stirring bar. The cells were
exposed to the murine serum at 37°C for
periods of up to 6 h under either aerobic or
hypoxic conditions. A humidified gas mixture
of either 95% air/5% CO2 or 95% N2/5%
CO2 (<10 pts/106 02) flowed through inlet
and outlet tubes in the stoppers of each vial
from 1 h before adding serum until the end
of the 6h exposure (Mohindra & Rauth,
1976). At various times cells were withdrawn
from the vials with a lOO1d pipette, centri-
fuged and resuspended in fresh medium.
Appropriate dilutions were plated in triplicate
Petri dishes. Estimates of cell survival were
obtained by counting stained colonies about
9 days later.
RESULTS
Misonidazole or Metronidazole alone
Data presented in the preceding paper
(Tannock, 1980) show that single-dose
MISO (1 mg/g), and multiple injections
of either MISO or METRO have no effect
on the growth of either the KHT or 16/C
tumours. Single-dose MISO given after
15 Gyradiation to the 16/C tumour led to a
small increase in delay to regrowth, im-
plying some ability to kill hypoxic cells
spared by radiation; in contrast, there
was no increase in growth delay compared
to irradiation alone of the KHT sarcoma
when single-dose MISO (1 mg/g) or mul-
tiple doses of either drug were given after
radiation. MISO and METRO in the dose
and schedule used were well tolerated, and
usually produced only transient weight
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FIG. 1. Growth curves for the KHT sarcoma in mice treated with saline (0), cyclophosphamide
(75 mg/kg) (e) or CY+MISO (1 mg/g) (A). The drugs were given simultaneously (A), or MISO
was given 4 h before CY (B). Means + s.e. are plotted for 7 mice.
loss, < 5%. Peripheral WBC counts after
MISO were within the normal range, but
means were slightly below control animals.
Cyclophosphamide
(i) Anti-tumour effects.-Both the KHT
and 16/C tumours responded to CY, and
at higher doses complete regressions and
growth delay of two weeks or more were
obtained. The combination of MISO
(1 mg/g) with CY led to increased delay to
regrowth of both tumours (Figs 1-3,
Table I). This effect was present when
MISO wasinjected up to 4 h before CY and
when the drugs were given simultaneously
(Figs 1 & 2). Further experiments with
the KHT tumour showed that the in-
creased anti-tumour effect of the drug
combination was lost if MISO was given
24 h before, or 2 h after CY.
Delay to regrowth of the KHT tumour
was also increased by combining CY with
the multiple dose schedule of MISO or
METRO (Table I, Fig. 3c); in these experi-
ments CY (50 or 75 mg/kg) was injected
with the 5th of 9 doses of the nitro-
imidazole. Despite the longer exposure of
tumour cells to MISO or METRO, this
schedule was no more effective for increas-
ing the anti-tumour effect of CY than a
single dose ofMISO.
In one experiment, CY was combined
with a course of multiple injections of
Ro-05-9963 (0.4 mg/kg x 9), the 0-de-
methylation product of MISO. There was
no significant increase in the anti-tumour
effect of CY or of host toxicity.
Further experiments were designed to
test whether MISO or METRO were
acting in part to kill hypoxic cells that
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FIG. 2.-Growth curves for the 16/C carcinoma in mice treated with saline (0), CY (100 mg/kg in A,
75 mg/kg in B) (A), MISO (1 mg/g) (0) or simultaneous CY+MISO (-). In (B) MISO was also
given 1 h before CY (V). Means + s.e. for groups of 6-8 mice are indicated.
were spared by CY. These experiments
compared treatment of the KHT tumour
with CY alone or combined with MISO or
METRO under the following conditions:
(a) Treatment ofsmall tumours that are
known to contain fewer hypoxic cells
(Hill, 1980).
(b) Use of lower doses ofMISO that are
known to be ineffective for killing
hypoxic cells.
(c) Treatment ofanimals that were kept
warm, because hypoxic-cell toxicity
of nitroimidazoles depends on tem-
perature, and peripheral tumours in
the leg might be cooler than core
body temperature (Stratford &
Adams, 1978).
The results of some of these experi-
ments are shown in Fig. 3, and do not
support a role for MISO or METRO in
killing hypoxic KHT cells. Treatment of
tumours on Day 5 after implantation
(before they were palpable) led to an equal
or greater increase in growth delay for
the drug combination than treatment of
larger tumours (Fig. 3A). The increase in
growth delay after adding MISO to
CY for treatment of 0 3-0 5 g tumours
depended on dose of MISO, but was
detectable at a dose of 0.5 mg/g body
weight (Fig. 3B). Maintaining animalsin an
incubator at 3700 for 4 h after treatment
with MISO (1 mg/g) led to death of the
animals: the warm environment presum-
ably prevented the known effect of MISO
in causing transient decrease in body
temperature, and confirms a previous
report of the toxicity of keeping animals
warm after MISO (Gomer & Johnson,
1979). Mice tolerated an environment of
350C for 4 h after single-dose MISO, or for
36 h during a course ofmultiple injections,
but it is not known whether the ambient
temperature of 350C led to an increase in
tumour temperature. There was no con-
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FIG. 3.-Growth curves for the KHT sarcoma treated with saline (0), CY (*) or CY+MISO (A) or
(CY+METRO) (V). Experimental conditions were as follows: (A) CY (75 mg/kg) and MISO
(1 mg/g) given to mice bearing non-palpable tumours on Day 5 after transplantation; (B) CY (75
mg/kg) and MISO (0.5 mg/g) given to mice bearing 04-0 5g tumours; (C) CY (75 mg/kg) and
METRO (0-4 mg/g x 9) given to mice bearing 0-3g tumours. One group ofmice (V) was kept at 35°C
throughout the 36h course of injections. CY was given simultaneously with MISO, or with the 5th
of 9 doses of METRO. Means + s.e. are plotted for 6-8 mice.
sistent change to delay in tumour re-
growth for mice kept warm during and
after treatment with CY alone, MISO or
METRO alone, or the combination, when
compared to experiments at room tem-
perature (e.g. Fig. 3C).
(ii) Host toxicity.-The addition of
MISO or METRO to treatment with CY
led to more deaths and more weight loss
(Table I). The increase in host toxicity
was greater for those conditions that led to
the larger increases in anti-tumour effects.
In an attempt to study the effect ofadding
MISO to CY on Therapeutic Index, growth
delay for the KHT sarcoma and host
toxicity were compared for a large dose
of CY, and a smaller dose combined with
MISO. CY at a dose of 200 mg/kg gave a
61
mean growth delay of 17-5 days, whereas
CY (75 mg/kg) +MISO (1 mg/g) gave
similar or greater toxicity, but caused
mean growth delay ofonly 10 days (Table
I). Therapeutic Index is thus lower for
combined treatment.
The addition ofMISO to CY also led to
greater myelosuppression. The serial re-
moval of small blood samples from the
tail veins of mice led to a fall in Hb and a
compensatory increase in WBC count, and
these effects were greater in mice with
tumours. MISO alone had no significant
effect on the Hb or WBC count, whereas
CY (75 mg/kg) caused a reduction in
WBC to a nadir at 3-4 days after treat-
ment, followed by rapid recovery. The
addition of MISO (1 mg/g) led to a sig-
I I~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
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TABLE 1.-Treatment-related death, weight loss and mean growth delay ofthe KHT sarcoma
after treatment with CY alone, or in combination with MISO or METRO
Mean tumour
growth delay*
(days)
(ranget)
CY (75 mg/kg) alone 6 (5-7)
CY (75 mg/kg)+MISO (0 5 mg/g) 8-5
CY (75 mg/kg)+MISO (1 mg/g) 10 (8-12)
CY (75 mg/kg)+MISO (0-2 mg/gx 9) 8 (7-8 5)
CY (75 mg/kg) +METRO (0.4 mg/g x 9) 9 (7 5-10)
CY (200 mg/kg) alone 17-5 (17-18)
% Weight loss
(ranget)
7 (3-12)
13
16 (10-21)
12 (10-15)
21 (19-23)
13 (10-16)
Proportion of
deaths from
treatmentt
1/53
0/8
13/64
1/15
3/15
2/15
* Displacement between tumour growth curves for treated and control animals at a tumour size of 1 g.
t Range of mean values from individual experiments.
t Deaths occurred 7-10 days after treatment. Deaths due to the tumour were not observed at this time.
100
50
8 20
a
10
20
V
__ 7/' --T
I_
2.0 _-
1.0
-4 0 2 3 4 5 6 7
Days after treatment
FIG. 4.-Total WBC count measured serially
on blood samples from tumour-bearing
C3H mice. Mice were treated with saline
(0), MISO (1 mg/g) (A), CY (75 mg/kg)
(0), or a combination of the drugs given
simultaneously (A). Means + s.e. for 7-8
samples are indicated.
nificant decrease in the nadir of WBC
count (Fig. 4). In several other experi-
ments the WBC and absolute polymorph
count were measured from blood smears
on the 3rd or 4th day after treatment with
CY, alone or in combination with single or
multiple doses ofMISO or METRO. In all
experiments the blood counts were lower
after combined treatment.
(iii) Mechanism.-Serum from mice
given CY was active against CHO cells
in vitro, and this system provides a bio-
assay for active metabolites of the drug.
The level of survival of CHO cells varied
slightly between experiments, and the
activity of the metabolites of CY decayed
even when serum was frozen immediately
after preparation. Thus, serum was pre-
pared as rapidly as possible before adding
to cultures of CHO cells in order to mini-
mize variability in time of preparation.
Serum from untreated mice, and from
mice that had received MISO (1 mg/g)
0 5 or 1.0 h earlier, had no effect on aerobic
or hypoxic CHO cells. This result is expec-
ted because the 1:16 dilution of the serum
in culture led to levels ofMISO much lower
than those usually lethal to hypoxic cells.
Serum from mice given CY (200 mg/kg) 0 5
h earlier was active, but most of this acti-
vity was lost 1 h after treatment (Fig.5).
Serum from mice that had received CY
and MISO had similar activity to serum
from mice receiving CY alone at 0 5 h, but
retained much greater activity at 1.0 h
(Fig. 5). There was little difference in
response ofaerobic and hypoxic cells. Thus
MISO seems to delay the excretion or
inhibit the breakdown of active metabo-
lites of CY.
BCNU
Anti-tumour effects and host toxicity.-
BCNU caused tumour regression and
876NITROIMIDAZOLES AND CHEMOTHERAPY
Vi
0Io I a
ta,~~~~
CZ)
0 2 4 6 0 2 4 6
Hours of exposure to murine serum
FIG. 5.-Survival of aerobic (open symbols) or hypoxic (closed symbols) CHO cells treated with
serum from mice that had received MISO 1 mg/g (V orV), CY 200 mg/kg (O or *) or both drugs
(A or *). (A) Data from 2 experiments for serum removed 0 5 h after treatment. (B) Data from
1 experiment for serum removed 10 h after treatment. (A repeat experiment gave qualitatively
similar results but a different level of survival after combined treatment.) Mean survival and range
of estimates from triplicate Petri dishes are plotted.
delayed growth of the KHT sarcoma (Lin
& Bruce, 1972) but experiments inthis and
other laboratories have shown the drug to
be inactive against the 16/C carcinoma
(Corbett et al., 1978). Combination of
BCNU with single-dose MISO led to a
marked increase in effectiveness against
the KHT tumour (Fig. 6 and Table II).
The nature of the anti-tumour inter-
action was investigated in experiments
analagous to those performed for CY.
The anti-tumour effects of BCNU and
MISO were observed when the drugs were
given together but not when MISO pre-
ceded BCNU by 4 h. MISO led to slightly
greater growth delay when combined with
BCNU for treatment ofsmallnon-palpable
tumours than for treatment of larger
tumours (Fig. 6). The increased effect of
the combination was dependent on the
dose of MISO, but was seen at doses of
05 or 075 mg/g (e.g. Fig. 6c).
The combination of BCNU and MISO
caused more deaths and more weight loss
than the same dose of BCNU alone (Table
II). For comparison ofTherapeutic Index,
the anti-tumour effects and toxicity of a
large dose of BCNU alone were compared
with those ofa smaller dose ofBCNIU with
MISO. The data ofTable II suggest about
equaltoxicityforthe samedelayin tumour
growth and hence no effect on Therapeutic
Index.
Treatment with BCNU had no effect on
Hb level, and caused only a small decrease
in WBC count. The addition ofMISO had
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FIG. 6.-Growth curves for the KHT sarcoma treated with saline (0), BCNU (I), or simultaneous
BCNU+MISO (A). Experimental conditions were as follows: (A) BCNU (20 mg/kg) and MISO
(1 mg/g) given to mice bearing . 0 3gtumours; (B) Same doses to micebearingnon-palpable tumours
on Day 5 after transplantation; (C) BCNU (33 mg/kg) and MISO (0 75 mg/g) given to mice bearing
0 4-0 5g tumours. Means + s.e. for groups of 6-8 mice are plotted.
little effect on the nadir of WBC count
after treatment (Table III).
(ii) Mechanism.-Serum from mice given
BCNU (66 mg/kg) 05 h earlier was active
against CHO cells in vitro, and there was
no difference in the response of aerobic
or hypoxic CHO cells (Fig. 7). Serum from
micetreated 1 hearlierwasinactive. Serum
from animals receiving combined treat-
ment 05 h before death (BCNU 66 mg/kg
+MISO 1 mg/g) had similar activity for
aerobic cells to that from mice receiving
BCNU alone, but was much more toxic for
hypoxic cells (Fig. 7). This unexpected
result has been confirmed in repeated
experiments. Thus MISO, at a dose that is
ineffective for killing hypoxic cells, seems
capable of selectively "sensitizing" hy-
poxic cells to the action ofBCNU.
The role of the above effect in causing
the increased anti-tumour effects in vivo
for the combination of BCNU and MISO
TABLE II.-Treatment-related death, weight loss, and mean growth delay of the KHT
sarcoma after treatment with BCNU alone, or in comnbination with MISO
Mean tumour
growth delay Proportion (
(days) % Weight loss deaths fron
(range) (range) treatment*
BCNU (20 mg/kg) alone 15 (1-5-2-0) 2 (0-6) 0/29
BCNU (20 mg/kg) +MISO (0 5 mg/g) 3-5 7 0/8
BCNU (20 mg/kg)+MISO (1 mg/g) 8-5 (7.5-10) 15 (11-19) 1/30
BCNU (33 mg/kg) alone 5 0 9 0/8
BCNU (33 mg/kg)+MISO (0 75 mg/g) 16-0 27 3/8
BCNU (50 mg/kg) alone 14.0 23 2/8
* Deaths within the first 2 weeks after treatment following progressive weight loss.
of
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TABLE Ill.-Total white blood cell count ( x 103) at various times after treatment with
BCNU (33 mg/kg) alone, or in combination with MISO (1 mg/g)
Controls
BCNU
BCNU+MISO
('I Q0-
1J3
10- CZ)
Day 2
10-4+ 0-6
7*9+ 03
99+ 0-6
3 E
Hours of exposure to murine serum
FIG. 7. Survival of aerobic (open symbols)
or hypoxic (closed symbols) CHO cells
treated with serum from mice that had
been treated with BCNU (66 mg/kg) with
1 mg/g MISO (triangles) or without
(circles). Mean and range from triplicate
Petri dishes are plotted.
cannot be determined. However, the
increase in host toxicity cannot easily be
explained by specific effects on hypoxic
cells, and other undetermined drug inter-
actions must be presumed.
DISCUSSION
I have shown that MISO or METRO
may influence the activity ofCY or BCNU
when the drugs are injected into mice.
The drug interactions lead to increased
responses of experimental tumours, but
Day 3
12-3+0-5
7-4+ 0-5
5-6+_ 05
Day4 Day6
12-6+0 5
5 9+0 4
5 4+ 0 5
12-4+ 0-8
10-1 + 0-6
10-9+0-5
also to increased toxicity. Combined treat-
ment does not lead to therapeutic advan-
tage, and may be detrimental.
The interaction of CY and MISO seems
to be due in part to a change in the
pharmacokinetics ofCY. Results presented
in Fig. 5, and confirmed in other experi-
ments, have shown thatthe administration
of MISO with CY leads to a longer reten-
tion in serum of metabolites toxic for
mammalian cells. This mechanism prob-
ably causes the increased growth delay
found in both experimental tumours, and
the increase in host toxicity, including
myelosuppression. The cause of the de-
crease in Therapeutic Index for the com-
bination of MISO and a moderate dose of
CY, as compared to a higher dose of CY
alone, is undetermined. The change in
pharmacokinetics might lead to selective
retention of those metabolites of CY that
have a high ratio of host toxicity to anti-
tumour effects, or there may be other
independent drug reactions that lead to an
increase in deaths and weight loss.
The interaction of BCNU and MISO is
complex. The combination has been shown
to cause an increase in non-specific host
toxicity, and the nature ofthis interaction
is unknown. However, MISO, at a con-
centration ineffective for killing hypoxic
cells, has been shown to give a selective
"sensitization" for the action of BCNU
against hypoxic cells. There was a similar
effect when BCNU and MISO were added
directly to cultures of CHO cells. Experi-
ments are being performedin tissue culture
to characterize this interaction, and will be
reported separately. BCNU was found to
spare hypoxic cells in one experimental
tumour (Hill & Stanley, 1975) but it
remains uncertain whether the observed
interaction of BCNU and MISO for
hypoxic cells is a cause of the increased
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activity of the combination for the KHT
tumour.
The present experiments, and those of
the previous paper (Tannock, 1980), were
undertaken to seek evidence for killing by
nitroimidazoles of hypoxic cells which
might have been spared by conventional
chemotherapy, and to provide data on
drug interactions prior to the use of such
combinations in man. There is little evi-
dence from the present experiments for
selective killing of hypoxic cells in murine
tumours by MISO or METRO given with
anti-cancer drugs, sinceanti-tumour effects
have been accompanied by equal or even
greater host toxicity. Little is known about
the relative responseofaerobicandhypoxic
clonogenic tumour cells to chemotherapy.
Such information is important, for if
surviving cells were predominantly hy-
poxic, nitroimidazoles and other drugs
should be selected and developed for their
hypoxic cell toxicity as well as for hypoxic-
cell radiosensitization. The added possi-
bility of hypoxic-cell "chemosensitiza-
tion", suggested by the above results for
BCNU and MISO is another potentially
exploitable mechanism, despite the lack
of therapeutic advantage for the KHT
sarcoma.
A major conclusion ofthe presentstudies
is that MISO or METRO lead to a marked
increase in host toxicity when combined
with several anti-cancer drugs. Combina-
tion of misonidazole or metronidazole
with cyclophosphamide or BCNU in
patients should be undertaken with great
caution, and should follow the design of a
Phase I trial.
I wish to thank Mrs P. Guttman for her expert
assistance and Dr R. P. Hill for constructive
criticism. Supported by a Reaserch Grant from the
National Cancer Institute of Canada.
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